Viking Acquisition Corp

Viking Acquisition Corp. II (NYSE: VII U) said it closed its $230 million IPO, selling 23,000,000 units at $10.00 each plus 3,000,000 units from the over-allotment option. Each unit includes one Class A share and one-third redeemable warrant; whole warrants buy shares at $11.50. Units traded July 2; shares/warrants expected to separate under VII and VII WS.

Viking Acquisition Corp. II (blank-check company) raised $230m in an NYSE IPO, selling 23m units at $10 each, per a press release. Each unit includes one Class A share and 1/3 warrant; whole warrants buy shares at $11.50. Units trade as VII U; shares and warrants expected to trade separately as VII and VII WS.

Viking Acquisition Corp. II (NYSE: VII U) priced its IPO of 20,000,000 units at $10.00 each, raising $200 million. Each unit includes one Class A share and 1/3 redeemable warrant; whole warrants buy shares at $11.50. Units trade July 2, 2026; offering closes July 6. Underwriters may add 3,000,000 units.

Robinhood is launching Robinhood Ventures Fund II (ticker RVII), a business development company offering 8 million shares at $25 each starting Aug. 13. The fund plans to raise $200 million, led by Goldman Sachs. It invests in Y Combinator-linked seed startups and charges a 2% management fee plus a 20% incentive fee, with estimated annual expenses of 4.18%. The prospectus labels the offering speculative and warns of potential discounts to net asset value.

Latigo Biotherapeutics (Nasdaq: LTGO) priced its IPO at $18 per share, raising $345.6 million, according to the IPO announcement. The company said the proceeds will fund its non-opioid painkiller program. Goldman Sachs, Jefferies, Leerink and Guggenheim served as bookrunners.

Ticketplus Ltd. (TP) priced its Nasdaq IPO at $8 per share, raising about $15 million by selling 1.875 million shares, according to the IPO pricing details. The offering is led by Roth Capital Partners with Bancroft Capital and MDB Capital, marking the company’s Nasdaq debut.